-
Publication Venue For
-
Partitioned glioma heritability shows subtype-specific enrichment in immune cells..
23:1304-1314.
2021
-
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience..
23:1252-1260.
2021
-
Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017..
23:990-998.
2021
-
A broad perspective on evaluating bias in the neuro-oncology workplace..
23:498-499.
2021
-
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank..
23:356-375.
2021
-
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial..
23:314-323.
2021
-
What is the Burden of Proof for Tumor Mutational Burden in gliomas?
2020
-
European genetic ancestry associated with risk of childhood ependymoma..
22:1637-1646.
2020
-
Response to Letter to Editor..
22:1706-1707.
2020
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017..
22:iv1-iv96.
2020
-
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas..
22:1262-1275.
2020
-
Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival..
22:1359-1367.
2020
-
Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma..
22:1233-1234.
2020
-
Receptor discordance in breast cancer brain metastases: when knowledge is power..
22:1060-1061.
2020
-
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases..
22:757-772.
2020
-
Germline cancer predisposition variants and pediatric glioma: a population-based study in California..
22:864-874.
2020
-
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study..
22:694-704.
2020
-
Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015..
22:301-302.
2020
-
Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis..
22:207-215.
2020
-
Pilocytic astrocytomas: where do they belong in cancer reporting?.
22:298-300.
2020
-
The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors..
21:1509-1518.
2019
-
Germline genetic landscape of pediatric central nervous system tumors..
21:1376-1388.
2019
-
Risk factors for childhood and adult primary brain tumors..
21:1357-1375.
2019
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016..
21:v1-v100.
2019
-
Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas..
21:1005-1015.
2019
-
Diet and risk of glioma: targets for prevention remain elusive..
21:832-833.
2019
-
Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines..
21:424-427.
2019
-
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas..
21:440-450.
2019
-
Sex-specific gene and pathway modeling of inherited glioma risk..
21:71-82.
2019
-
Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool..
20:1652-1660.
2018
-
Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014..
20:vii6-vii16.
2018
-
Genome-wide association analysis identifies a meningioma risk locus at 11p15.5..
20:1485-1493.
2018
-
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma..
20:1547-1555.
2018
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015..
20:iv1-iv86.
2018
-
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686..
20:1400-1410.
2018
-
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma..
20:1411-1418.
2018
-
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium..
20:873-884.
2018
-
Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence..
20:942-953.
2018
-
Recent advances in intradural spinal tumors..
20:729-742.
2018
-
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas..
20:632-641.
2018
-
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143..
20:674-686.
2018
-
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades..
20:687-694.
2018
-
Females have the survival advantage in glioblastoma..
20:576-577.
2018
-
The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone..
20:295-298.
2018
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy..
20:249-258.
2018
-
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy..
20:259-267.
2018
-
Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report..
20:132-142.
2018
-
Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study..
19:1673-1682.
2017
-
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014..
19:v1-v88.
2017
-
Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007..
19:1553-1564.
2017
-
Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma..
19:1503-1510.
2017
-
Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis..
19:1391-1397.
2017
-
The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival..
19:1217-1227.
2017
-
Integrated genomic analysis of survival outliers in glioblastoma..
19:833-844.
2017
-
Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010..
19:726-735.
2017
-
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study..
19:689-698.
2017
-
The radiosurgery fractionation quandary: single fraction or hypofractionation?.
19:ii38-ii49.
2017
-
Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults..
19:31-42.
2017
-
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013..
18:v1-v75.
2016
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies..
18:1357-1366.
2016
-
Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation..
18:507-517.
2016
-
American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012..
18 Suppl 1:i1-i50.
2016
-
Isocitrate dehydrogenase mutations in gliomas..
18:16-26.
2016
-
Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010..
18:70-77.
2016
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment..
17:1538-1539.
2015
-
Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival..
17:1525-1537.
2015
-
Telomere maintenance and the etiology of adult glioma..
17:1445-1452.
2015
-
Vaccination strategies for neuro-oncology..
17 Suppl 7:vii15-vii25.
2015
-
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012..
17 Suppl 4:iv1-iv62.
2015
-
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials..
17:1188-1198.
2015
-
Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States..
17:1166-1173.
2015
-
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial..
17:1148-1156.
2015
-
Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma..
17:1043-1045.
2015
-
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study..
17:854-861.
2015
-
Response to "the epidemiology of glioma in adults: a 'state of the science' review"..
17:624-626.
2015
-
Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011..
16 Suppl 10:x1-x36.
2015
-
Immunotherapy advances for glioblastoma..
16:1441-1458.
2014
-
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011..
16 Suppl 4:iv1-i63.
2014
-
Epidermal growth factor receptor and variant III targeted immunotherapy..
16 Suppl 8:viii20-viii25.
2014
-
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer..
16:1333-1340.
2014
-
The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010..
16:1392-1399.
2014
-
Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma..
16:1129-1136.
2014
-
Identification and preliminary treatment data of xenografts representing tcga-defined subtypes..
16 Suppl 3:iii35.
2014
-
Idh1 mutations as a immunotherapeutic target for brain tumors..
16 Suppl 3:iii40.
2014
-
Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration..
16 Suppl 3:iii43.
2014
-
Oncolytic poliovirus immunotherapy of glioblastoma..
16 Suppl 3:iii41.
2014
-
Patient-derived xenografts mirror the proteomic profile of human glioblastoma: implications for personalized drug development..
16 Suppl 3:iii38.
2014
-
Prognostic marker analysis in pediatric posterior fossa ependymomas..
16 Suppl 3:iii27.
2014
-
Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal..
16 Suppl 3:iii5-iii6.
2014
-
The epidemiology of glioma in adults: a "state of the science" review..
16:896-913.
2014
-
Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial"..
16:169-170.
2014
-
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study..
16:310-317.
2014
-
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010..
15 Suppl 2:ii1-i56.
2013
-
Imaging descriptors improve the predictive power of survival models for glioblastoma patients..
15:1389-1394.
2013
-
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis..
15:1041-1047.
2013
-
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study..
15:945-954.
2013
-
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677..
15:936-944.
2013
-
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology..
15:535-541.
2013
-
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma..
15:242-250.
2013
-
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study..
14:1404-1412.
2012
-
High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival..
13:1296-1307.
2011
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab..
13:660-668.
2011
-
Clinical trial end points for high-grade glioma: the evolving landscape..
13:353-361.
2011
-
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma..
13:324-333.
2011
-
Risk factors for oligodendroglial tumors: a pooled international study..
13:242-250.
2011
-
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?.
13:3-13.
2011
-
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab..
13:143-151.
2011
-
Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma..
12:1311-1317.
2010
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma..
12:1300-1310.
2010
-
HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea..
12:956-966.
2010
-
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma..
12:871-881.
2010
-
Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses..
12:664-678.
2010
-
Assessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy..
12:145-152.
2010
-
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
2021
-
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
2020
-
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
2016
-
RANDOMIZATION OF PATIENTS WITH GLIOBLASTOMA TO VACCINE SITE PRE-CONDITIONING WITH TETANUS-DIPHTHERIA TOXOID SYSTEMICALLY ENHANCES MIGRATION AND THERAPEUTIC EFFECT OF CYTOMEGALOVIRUS PP65-PULSED DENDRITIC CELL VACCINE IN A MIP-1α-DEPENDENT FASHION.
2014